ERBB2 and non-small cell lung carcinoma: To our knowledge, this case represents the first published report detailing the use of a combination osimertinib and fam-trastuzumab-deruxtecan for the treatment of EGFR and HER2-mutated NSCLC after progression on osimertinib.